TransCode Therapeutics, Inc. carries no debt; cash flow comfortably covers obligations.

TransCode Therapeutics, Inc.'s free cash flow has decreased 46.15% from $-13.36M last year to $-19.52M, signaling decreasing performance

TransCode Therapeutics, Inc.'s debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability.

TransCode Therapeutics, Inc.'s debt has increased relative to shareholder equity from -0.02 last year to 0.00 today, signaling weakened financials

TransCode Therapeutics, Inc. has a net cash position, so leverage is healthy.

TransCode Therapeutics, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

TransCode Therapeutics, Inc. has insufficient data to evaluate this check.

TransCode Therapeutics, Inc.'s short-term assets of $21.98M exceed its short-term liabilities of $3.49M

TransCode Therapeutics, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

TransCode Therapeutics, Inc.'s return on equity of -99.39%, is lower than 15.00%, indicating bad performance

TransCode Therapeutics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

TransCode Therapeutics, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

TransCode Therapeutics, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

TransCode Therapeutics, Inc. has negative free cash flow, indicating cash burn

TransCode Therapeutics, Inc.'s yearly earnings has decreased 106.87% since last year from $-16.75M to $-34.66M, signaling decreasing performance

TransCode Therapeutics, Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -21.17% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

TransCode Therapeutics, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

TransCode Therapeutics, Inc. had revenue growth in 5 out of 5 years, indicating consistent revenue performance

TransCode Therapeutics, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

TransCode Therapeutics, Inc. is undervalued relative to its fair value price of 16.81K based on Discounted Cash Flow model

TransCode Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

TransCode Therapeutics, Inc. is undervalued relative to its fair value price of 19.28K based on EBITDA multiple model

TransCode Therapeutics, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

TransCode Therapeutics, Inc. has insufficient data to evaluate this check.

TransCode Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

TransCode Therapeutics, Inc. has a price-to-book ratio of 0.02x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

TransCode Therapeutics, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue